Novocure Ltd

NVCRNASDAQ NMS - GLOBAL MARKET

Health CareHealth Care

$17.04

-0.210000 (-1.22%)

As of 05/29/26 EDT · USD

Compare

52-Week Low: $9.82Current: $17.0452-Week High: $19.25

Key Statistics

Open

$17.22

Day High

$17.65

Day Low

$16.86

Prev. Close

$17.25

Volume

1.28M

Avg. Volume

—

Market Cap

$1.97B

P/E (TTM)

-11.10

Forward P/E

—

P/B Ratio

—

52W High

$19.25

52W Low

$9.82

50D MA

$14.00

200D MA

$13.00

Dividend Yield

—

Beta

—

Performance

-4.8%

+42.8%

+34.8%

YTD

+29.9%

-10.8%

About

Alternating electric field therapy, sometimes called tumor treating fields (TTFields), is a type of electromagnetic field therapy using low-intensity, intermediate frequency electrical fields to treat cancer. TTFields disrupt cell division by disrupting dipole alignment and inducing dielectrophoresis of critical molecules and organelles during mitosis. These anti-mitotic effects lead to cell death, slowing cancer growth. A TTField-treatment device manufactured by the Israeli company Novocure is approved in the United States and Europe for the treatment of newly diagnosed and recurrent glioblastoma, malignant pleural mesothelioma (MPM), and is undergoing clinical trials for several other tumor types. Despite earning regulatory approval, the efficacy of this technology remains controversial among medical experts.

www.novocure.com/